Lv4
746 积分 2024-09-18 加入
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
25天前
已完结
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
25天前
已完结
The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development
26天前
已完结
免疫检查点抑制剂用于进展期胃癌围手术期治疗的中国专家共识（2024版）
28天前
已完结
JK5G postbiotics attenuate immune-related adverse events in NSCLC patients by regulating gut microbiota: a randomized controlled trial in China
29天前
已完结
2022年中国恶性肿瘤流行情况分析
30天前
已完结
Cancer statistics, 2024
30天前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
1个月前
已完结
The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023
1个月前
已完结
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
1个月前
已完结
皖公网安备34019202002308
